Form Type:  SC 13G/A
Filing Date:  2/16/2021 
CIK:  0001724521 
Address:  3928 POINT EDEN WAY 
City, State, Zip:  HAYWARD, California 94545 
Telephone:  (510) 694-6200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.87 (3.15%)  
Trade Time: 
May 14  
Market Cap: 
Trade RCUS now with 

© 2021  
Description of Business
We are a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. Our initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. We have built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which we have the ability to develop in combinations with our monoclonal antibodies through rationally designed, indication-specific trial designs. Our vision is to create, develop and commercialize highly differentiated combination cancer therapies. Our Clinical Development Pipeline The following chart summarizes our clinical pipeline. In 2020, we entered into an Option, License and Collaboration Agreement (Gilead Collaboration Agreement) with Gilead Sciences, Inc.
Register and access this filing in:     
  EXHIBIT 99.1